Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD

Background and Objectives : Non-alcoholic fatty liver disease (NAFLD) is associated with inflammation and subsequent increase in cardiovascular risk. Because of its widespread presence and distribution, invasive diagnostic procedures (i.e., liver biopsy) are reserved for a limited number of subjects. With liver ultrasound, Fatty liver index (FLI) and fibrosis-4 (FIB-4) scores non-invasively assess liver steatosis and fibrosis. We aimed to evaluate the changes in inflammatory markers and FLI/FIB-4 scores in non-obese metformin-treated type 2 diabetes patients (T2DM) with NAFLD. Methods: All subjects underwent abdominal ultrasound aiming for NAFLD stratification (grade 1 to 3 according to its severity). Metabolic parameters (morning glycaemia, HbA1C, lipids, liver function tests) and serum inflammatory markers (C-reactive protein, ferritin, and nitric oxide), and FLI/FIB-4 are calculated. Results: FLI score and ultrasound NAFLD grades correlated (p<0.05). We observed a significant correlation between the levels of ferritin and C-reactive protein (CRP) (p<0.05), and the FLI (p<0.05). Body weight (BW) (p<0.05), waist circumference (WC) (p<0.05), the levels of HbA1c (p<0.05), transferrin (p<0.05), insulin (p<0.05), and FLI score (p<0.05) significantly differed between groups defined by the severity of NAFLD. Conclusion: This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD.

Download Full-text

Diagnostic accuracy of serum inflammatory markers in late fracture-related infection

The Bone & Joint Journal ◽

10.1302/0301-620x.100b12.bjj-2018-0586.r1 ◽

2018 ◽

Vol 100-B (12) ◽

pp. 1542-1550 ◽

Cited By ~ 13

Author(s):

J. van den Kieboom ◽

P. Bosch ◽

J. D. J. Plate ◽

F. F. A. IJpma ◽

R. Kuehl ◽

...

Keyword(s):

Diagnostic Accuracy ◽

Sensitivity And Specificity ◽

Inflammatory Markers ◽

Meta Analysis ◽

Diagnostic Value ◽

Mixed Effects Models ◽

C Reactive Protein ◽

Reactive Protein ◽

Erythrocyte Sedimentation ◽

Serum Inflammatory Markers

Aims To assess the diagnostic value of C-reactive protein (CRP), leucocyte count (LC), and erythrocyte sedimentation rate (ESR) in late fracture-related infection (FRI). Materials and Methods PubMed, Embase, and Cochrane databases were searched focusing on the diagnostic value of CRP, LC, and ESR in late FRI. Sensitivity and specificity combinations were extracted for each marker. Average estimates were obtained using bivariate mixed effects models. Results A total of 8284 articles were identified but only six were suitable for inclusion. Sensitivity of CRP ranged from 60.0% to 100.0% and specificity from 34.3% to 85.7% in all publications considered. Five articles were pooled for meta-analysis, showing a sensitivity and specificity of 77.0% and 67.9%, respectively. For LC, this was 22.9% to 72.6%, and 73.5% to 85.7%, respectively, in five articles. Four articles were pooled for meta-analysis, resulting in a 51.7% sensitivity and 67.1% specificity. For ESR, sensitivity and specificity ranged from 37.1% to 100.0% and 59.0% to 85.0%, respectively, in five articles. Three articles were pooled in meta-analysis, showing a 45.1% sensitivity and 79.3% specificity. Four articles analyzed the value of combined inflammatory markers, reporting an increased diagnostic accuracy. These results could not be pooled due to heterogeneity. Conclusion The serum inflammatory markers CRP, LC, and ESR are insufficiently accurate to diagnose late FRI, but they may be used as a suggestive sign in its diagnosis.

Download Full-text

691 Clinical significance of high sensitivity C-reactive protein (hs-CRP) in non-alcoholic fatty liver disease (NAFLD)

Journal of Hepatology ◽

10.1016/s0168-8278(06)80691-4 ◽

2006 ◽

Vol 44 ◽

pp. S255

Author(s):

T. Kogiso ◽

Y. Morivoshi ◽

H. Nagahara

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Clinical Significance ◽

Fatty Liver Disease ◽

High Sensitivity ◽

C Reactive Protein ◽

Alcoholic Fatty Liver ◽

Reactive Protein ◽

Hs Crp ◽

Alcoholic Fatty Liver Disease

Download Full-text

Reply to: “C-reactive protein levels in non-alcoholic fatty liver disease”

Journal of Hepatology ◽

10.1016/j.jhep.2011.07.022 ◽

2012 ◽

Vol 56 (2) ◽

pp. 508-510

Author(s):

Tine Jess ◽

Esther Zimmermann ◽

Rodolphe Anty ◽

Joan Tordjman ◽

An Verrijken ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

C Reactive Protein ◽

Alcoholic Fatty Liver ◽

Protein Levels ◽

Reactive Protein ◽

Alcoholic Fatty Liver Disease

Download Full-text

Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15527 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15527-e15527

Author(s):

Ryuichi Mizuno ◽

Go Kimura ◽

Tsunenori Kondo ◽

Takeshi Ueda ◽

Hidehiko Hara ◽

...

Keyword(s):

Interleukin 6 ◽

Inflammatory Markers ◽

Progression Free Survival ◽

High Sensitivity ◽

C Reactive Protein ◽

First Line ◽

Free Survival ◽

Reactive Protein ◽

Hs Crp ◽

Serum Inflammatory Markers

e15527 Background: Predicting the efficacy of tyrosine kinase inhibitors (TKI) would be of clinical value in patients with metastatic renal cell carcinoma (mRCC). We tested the hypothesis that serum inflammatory markers are associated with clinical outcome in mRCC patients at favorable or intermediate prognostic risk treated with first-line sunitinib. Methods: Eighty-nine mRCC patients were prospectively monitored at baseline (day 0) during sunitinib treatment. Serum interleukin-6 and 8 levels were determined by CLEIA and ELISA, respectively. A high-sensitivity C-reactive protein (hs-CRP) levels were measured using laser nephelometry. Correlations between baseline interleukin-6, 8, hs-CRP levels and response to sunitinib, and progression-free survival (PFS) were examined. Results: Median PFS was 9.2 months. Clinical benefit rate (CBR; percent complete responses+partial responses +stable disease 24 weeks) was 57.3%. Baseline interleukin-8 (P=0.0240) and hs-CRP (P=0.0060) was associated with CBR. No association between baseline interleukin-6 and 8 with PFS was observed. However, baseline hs-CRP were associated with PFS (P=0.0016; unit risk 1.010; 95% CI 1.004 to 1.017). Conclusions: Baseline serum inflammatory markers could be of clinical interest in sunitinib-treated mRCC patiens to predict outcome. Baseline hs-CRP serum levels warrant further study. Clinical trial information: UMIN000009622.

Download Full-text